Insider

Thermo Fisher Scientific reports third-quarter profit growth

Thermo Fisher Scientific Inc. reported third-quarter 2026 revenue of $12.1 billion, up 9.1% year-over-year. Operating income rose 16.6% to $2.3 billion, and net income increased 6.5% to $1.7 billion, resulting in diluted earnings per share (EPS) of $4.64.

Verified against 5 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a machine in a room
Photo by RephiLe water on Unsplash
$12.1 billion
Third quarter revenue
$2.3 billion
Operating income
$1.7 billion
Net income

Key points

  • The company posted positive financial results for the third quarter of 2026, which ended September 26.
  • GAAP and adjusted operating margins rose due to productivity improvements and lower restructuring charges.

Third-quarter financial results

The company posted positive financial results for the third quarter of 2026, which ended September 26. Growth was supported by strong customer activity across all key markets, particularly in Asia-Pacific. Organic revenue growth was led by the Laboratory Products and Biopharma Services and Analytical Instruments segments.

Quarter vs the same quarter a year earlier

Jun–Sep 2025Jun–Sep 2026Revenue+9.1%$11.1B$12.1BOperating income+16.6%$1.9B$2.3BNet income+6.5%$1.6B$1.7B
Data from the original sources listed alongside.

Revenue by quarter, $B

11.4Q4 '24*17.7%10.4Q1 '2516.6%10.9Q2 '2516.9%11.1Q3 '2517.5%12.2Q4 '25*18.5%11Q1 '2616.9%12Q2 '2617.4%12.1Q3 '2618.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Operating efficiency and corporate changes

GAAP and adjusted operating margins rose due to productivity improvements and lower restructuring charges. The company notes in its report that the impact of strategic investments and losses from assets held for sale may offset the benefits of cost optimization.

Previously, on August 12, 2026, the company completed the sale of its microbiology business to Astorg. Executive Vice President Michael D. Shafer announced his intent to retire on December 31, 2026. Also in the reporting period, officer Britt Lisa P. sold 2,831 shares, and director Scott M. Sperling gifted 3,490 shares.

Next steps for analysis

To evaluate future performance, watch financial reports, particularly operating margin and organic revenue growth in key segments, as these reflect the company's ability to maintain efficiency despite strategic investments.

Original sources

  1. financial data (XBRL)October 30, 2026SHA-256 of our archived copy b1745fea7876…
  2. 8-K filing, October 30, 2026October 30, 2026SHA-256 of our archived copy 16a3d79d87ec…
  3. 10-Q filing, October 30, 2026October 30, 2026SHA-256 of our archived copy 3b7f0d0f1d66…
  4. 4 filing, October 30, 2026October 30, 2026SHA-256 of our archived copy bd5cd674770d…
  5. 4 filing, October 30, 2026October 30, 2026SHA-256 of our archived copy 12a18ee9cc1f…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards